Literature DB >> 1537914

Sensitive microculture method for isolation of human immunodeficiency virus type 1 from blood leukocytes.

A Erice1, K J Sannerud, V L Leske, D Aeppli, H H Balfour.   

Abstract

A study was conducted to compare our standard culture with a new microculture procedure for isolation of human immunodeficiency virus type 1 (HIV-1) from blood leukocytes. A total of 137 blood specimens from 102 HIV-1 antibody-positive individuals (52 were asymptomatic, 31 were symptomatic, and 19 had AIDS) were cultured in a microculture system in which 10(6) of the patients' peripheral blood mononuclear cells (PBMC) were cocultured with 10(6) phytohemagglutinin (PHA)-stimulated PBMC from an HIV-1 antibody-negative blood donor in 1.2 ml of culture medium. Results were compared with those of a historical control group of 139 standard HIV-1 cultures from 108 HIV-1 antibody-positive subjects (58 were asymptomatic, 36 were symptomatic, and 14 had AIDS). For standard cultures, 10 x 10(6) of the patients' PBMC were cocultured with 5 x 10(6) PHA-stimulated PBMC from an HIV-1 antibody-negative blood donor in 15 ml of culture medium. HIV-1 was isolated in 128 (93%) microcultures and 133 (96%) standard cultures. Both methods identified more than 75% of the positive cultures within 7 days and 100% of the positive cultures within 14 days. The isolation rates for HIV-1 in microcultures compared with standard cultures were 91 versus 93% (specimens from asymptomatic individuals), 93 versus 96% (specimens from symptomatic individuals), and 97 versus 100% (specimens from patients with AIDS). The median time to positivity for both culture methods was 7 days, and this correlated significantly with symptoms and CD4+ cell counts. The microculture method is a sensitive and less expensive system for isolation of HIV-1 from PBMC of HIV-1 antibody-positive individuals, and we recommend it as the culture method of choice, especially for children and patients with AIDS and severe anemia or leukopenia whose blood volume is an important consideration.

Entities:  

Mesh:

Year:  1992        PMID: 1537914      PMCID: PMC265075          DOI: 10.1128/jcm.30.2.444-448.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection.

Authors:  J Goudsmit; J M Lange; D A Paul; G J Dawson
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

Review 2.  Pathogenesis of infection with human immunodeficiency virus.

Authors:  D D Ho; R J Pomerantz; J C Kaplan
Journal:  N Engl J Med       Date:  1987-07-30       Impact factor: 91.245

Review 3.  NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection.

Authors:  A S Fauci; S M Schnittman; G Poli; S Koenig; G Pantaleo
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

4.  Isolation of HIV-1 from the blood of seropositive adults: patient stage of illness and sample inoculum size are major determinants of a positive culture. The Walter Reed Retroviral Research Group.

Authors:  D S Burke; A K Fowler; R R Redfield; S Dilworth; C N Oster
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

5.  Efficient isolation of HIV from plasma during different stages of HIV infection.

Authors:  A Ehrnst; A Sönnerborg; S Bergdahl; O Strannegård
Journal:  J Med Virol       Date:  1988-09       Impact factor: 2.327

6.  Human immunodeficiency virus type 1 (HIV-1) infection a median of 18 months before a diagnostic western blot. Evidence from a cohort of homosexual men.

Authors:  S M Wolinsky; C R Rinaldo; S Kwok; J J Sninsky; P Gupta; D Imagawa; H Farzadegan; L P Jacobson; K S Grovit; M H Lee
Journal:  Ann Intern Med       Date:  1989-12-15       Impact factor: 25.391

7.  Recovery of human immunodeficiency virus from ocular tissues in patients with acquired immune deficiency syndrome.

Authors:  H L Cantrill; K Henry; B Jackson; A Erice; F M Ussery; H H Balfour
Journal:  Ophthalmology       Date:  1988-10       Impact factor: 12.079

8.  Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome.

Authors:  D D Ho; T R Rota; R T Schooley; J C Kaplan; J D Allan; J E Groopman; L Resnick; D Felsenstein; C A Andrews; M S Hirsch
Journal:  N Engl J Med       Date:  1985-12-12       Impact factor: 91.245

9.  HTLV-III in the semen and blood of a healthy homosexual man.

Authors:  D D Ho; R T Schooley; T R Rota; J C Kaplan; T Flynn; S Z Salahuddin; M A Gonda; M S Hirsch
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

10.  HTLV-III in cells cultured from semen of two patients with AIDS.

Authors:  D Zagury; J Bernard; J Leibowitch; B Safai; J E Groopman; M Feldman; M G Sarngadharan; R C Gallo
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

View more
  8 in total

1.  Pilot studies for development of an HIV subtype panel for surveillance of global diversity.

Authors:  Mark Manak; Silvana Sina; Bharathi Anekella; Indira Hewlett; Eric Sanders-Buell; Viswanath Ragupathy; Jerome Kim; Marion Vermeulen; Susan L Stramer; Ester Sabino; Piotr Grabarczyk; Nelson Michael; Sheila Peel; Patricia Garrett; Sodsai Tovanabutra; Michael P Busch; Marco Schito
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-24       Impact factor: 2.205

2.  Comparison of blood collected in acid-citrate-dextrose and EDTA for use in human immunodeficiency virus peripheral blood mononuclear cell cultures.

Authors:  S A Fiscus; H Chakraborty; R Shepard; M Goodman
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Length of incubation time for human immunodeficiency virus cultures.

Authors:  S A Fiscus; S L Welles; S A Spector; J L Lathey
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

4.  Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China.

Authors:  Sihong Xu; Jingyun Li; Zuoyi Bao; Hui Xing; Ping Zhong; Hanping Li; Haiwei Zhou; Xinping Li; Sharon Wu; Aijing Song; Xiuhua Li; Jianhui Nie; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2010-02-01       Impact factor: 4.074

5.  Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group.

Authors:  W A Scott; D Brambilla; E Siwak; C Beatty; J Bremer; R W Coombs; H Farzadegan; S A Fiscus; S M Hammer; F B Hollinger; N Khan; S Rasheed; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

6.  TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus.

Authors:  F M Uckun; L M Chelstrom; L Tuel-Ahlgren; I Dibirdik; J D Irvin; M C Langlie; D E Myers
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

7.  Prospective study of antigenemia, plasma viremia and lymphocytic viremia in HIV-infected hemophiliacs.

Authors:  S Melón Garcia; M de Oña Navarro; C Rodriguez Pinto; M Fernández Urgellés; A Martinez Gutierrez; P de la Iglesia; F J Mendez García
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

8.  Isolation, characterization, and transmission of human T-lymphotropic virus types I and II in culture.

Authors:  K Kitamura; D L Rudolph; C Goldsmith; T M Folks; R B Lal
Journal:  Curr Microbiol       Date:  1993-12       Impact factor: 2.188

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.